EVerZom

EVerZom

Biotechnologie

Paris, Ile-de-France 4 622 abonnés

Revolutionizing healthcare with exosomes focusing on gastrointestinal, liver and kidney regeneration

À propos

EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.

Secteur
Biotechnologie
Taille de l’entreprise
11-50 employés
Siège social
Paris, Ile-de-France
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2019
Domaines
extracellular vesicles, exosomes, bioproduction, drug delivery, regenerative medecine, biodrugs et cell culture

Lieux

Employés chez EVerZom

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

EVerZom 2 rounds en tout

Dernier round

Subside

2 841 962,00 $US

Voir plus d’informations sur Crunchbase